Five reasons why an Indian pioglitazone flip-flop is bad practice
This article was originally published in Scrip
Executive Summary
India's possible regulatory flip-flop over the diabetes drug, pioglitazone, raises many serious questions on the scientific evaluation process involved in such decisions and underscores the need for widespread studies to generate country-specific adverse drug reaction (ADR) data.